M
Maverick Therapeutics
Developing next-generation T-cell engaging bispecific antibody therapeutics for solid tumor cancers
About Maverick Therapeutics
Maverick Therapeutics is a preclinical stage biotech company specializing in the development of next-generation T cell redirecting antibody therapeutics. The company focuses on creating innovative solutions for patients suffering from solid tumor cancers. Maverick Therapeutics operates in the biotechnology sector, targeting healthcare providers and patients as its primary clients. The business model revolves around pioneering bispecific T cell engaging platforms, which are designed to enhance the body's immune response against cancer cells. Revenue is generated through research and development partnerships, grants, and potential future commercialization of its therapeutic products.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Brisbane, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
MPM BioImpact
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Maverick Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Maverick Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.